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SUMMARY
Pathogenic bacteria commonly deploy enzymes to promote viru-
lence. These enzymes can modulate the functions of host cell tar-
gets. While the actions of some enzymes can be very obvious (e.g.,
digesting plant cell walls), others have more subtle activities. De-
pending on the lifestyle of the bacteria, these subtle modifications
can be crucially important for pathogenesis. In particular, if bac-
teria rely on a living host, subtle mechanisms to alter host cellular
function are likely to dominate. Several bacterial virulence factors
have evolved to use enzymatic deamidation as a subtle posttrans-
lational mechanism to modify the functions of host protein tar-
gets. Deamidation is the irreversible conversion of the amino acids
glutamine and asparagine to glutamic acid and aspartic acid, re-
spectively. Interestingly, all currently characterized bacterial
deamidases affect the function of the target protein by modifying
a single glutamine residue in the sequence. Deamidation of target
host proteins can disrupt host signaling and downstream pro-
cesses by either activating or inactivating the target. Despite the
subtlety of this modification, it has been shown to cause dramatic,
context-dependent effects on host cells. Several crystal structures
of bacterial deamidases have been solved. All are members of the
papain-like superfamily and display a cysteine-based catalytic
triad. However, these proteins form distinct structural subfamilies
and feature combinations of modular domains of various func-
tions. Based on the diverse pathogens that use deamidation as a
mechanism to promote virulence and the recent identification of
multiple deamidases, it is clear that this enzymatic activity is
emerging as an important and widespread feature in bacterial
pathogenesis.
INTRODUCTION
Many bacterial pathogens use diverse suites of virulence fac-tors to contribute to pathogenicity. These virulence factors
include toxins and type III effectors, which are proteins injected
into host cells via specialized type III secretion systems. Effectors
often modify eukaryotic host target proteins with posttransla-
tional modifications that alter normal cellular function. Com-
monly described posttranslational modifications utilized by effec-
tors include ubiquitination, acetylation, and AMPylation (1–3).
Recently, enzymatic deamidation has emerged as a common post-
translational modification utilized by a broad range of bacterial
pathogens of both plants and animals to alter the functions of host
proteins. Deamidation is the replacement of an amide group with
a carboxylate group (Fig. 1). Therefore, it converts glutamine and
asparagine to glutamic acid and aspartic acid, respectively. This
irreversible amino acid conversion results in an increase of ap-
proximately 1 Da in the mass of the target protein, an increase in
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the negative charge of the target protein, and the release of ammo-
nia. Nonspecific deamidation can occur spontaneously as pro-
teins age and are degraded (4). In contrast, specific enzymatic
deamidation can regulate normal cellular functions, such as che-
motaxis and protein turnover in prokaryotes, or disrupt eukary-
otic host cell function during infection (5, 6). Here we focus on
deamidases that contribute to bacterial virulence.
The topic of this review is the six currently known families of
bacterial virulence factors that use deamidation to modulate host
functions during infection (Table 1). Cytotoxic necrotizing fac-
tors (CNFs) are a family of deamidases from Escherichia coli
(CNF1, -2, and -3) and Yersinia pseudotuberculosis (CNFY). The
CNFs target a glutamine residue (either Gln63 or Gln61) in the
switch II domain of GTPase proteins that is critical for function (7,
8). Deamidation of this glutamine leads to constitutive activation
of the target GTPases, resulting in cytoskeletal rearrangements.
Reorganization of the actin cytoskeleton is one mechanism used
by invasive bacteria to promote entry into host cells (9, 10). BLF1
is a toxin from Burkholderia pseudomallei that is lethal to mice and
tissue culture cells (11). BLF1 inhibits host protein synthesis via
deamidation of eIF4A (11). VopC is a type III effector from Vibrio
parahaemolyticus that deamidates and constitutively activates
small GTPases (12). Pasteurella multocida toxin (PMT) is the ma-
jor virulence factor of Pasteurella multocida, the causal agent of a
variety of mammalian and avian diseases. PMT constitutively ac-
tivates various G proteins, including Gq/11, Gi, and G12/13, via
deamidation of a glutamine that is also in the switch II region (13).
Cell cycle-inhibiting factors (Cifs) are type III effectors and cyclo-
modulins from multiple bacterial species. Cifs inhibit ubiquitina-
tion pathways by deamidating glutamine 40 of ubiquitin and the
ubiquitin-like protein NEDD8 (14). OspI is a type III effector
protein from Shigella flexneri that dampens host immune re-
sponses by deamidating UBC13 and disrupting the TRAF6-medi-
ated signaling pathway (15). We review the details of each of these
six families, specifically with respect to their three-dimensional
structures and the impact that deamidation has on the functions
of their host target proteins. We conclude that deamidation, as a
nonreversible modification, is likely an “all or nothing” virulence
switch to alter diverse cellular functions across diverse pathosys-
tems.
CYTOTOXIC NECROTIZING FACTOR TOXINS
Cytotoxic Necrotizing Factor Toxins Deamidate Rho
GTPases
CNF1 from E. coli was the first bacterial deamidase identified (7,
8). CNF1 is expressed in uropathogenic strains of E. coli (16).
Following the discovery of CNF1, a number of homologs were
identified in different strains of E. coli. For example, CNF2 is pro-
duced by enteropathogenic E. coli (EPEC) strains isolated from
cows and sheep (17). The amino acid sequence of CNF2 is 85%
identical to that of CNF1. CNF3 was isolated from a necrotoxi-
genic E. coli strain that infects sheep and goats (18). CNF3 shares
70% amino acid identity with CNF1. Interestingly, CNFs are not
restricted to E. coli. Yersinia pseudotuberculosis produces CNFY,
which is 61% identical to CNF1 (19). Furthermore, dermonecro-
tizing toxin (DNT) from Bordetella is a virulence factor that also
shares sequence homology with CNF1. However, DNT behaves
most efficiently as a transglutaminase in vitro, being active in the
presence of polyamines (20, 21). Therefore, we do not include a
detailed discussion of DNT here.
Schmidt et al. and Flatau et al. demonstrated that CNF1 con-
verts Gln63 of the critical RhoA GTPase switch II region to glu-
tamic acid via enzymatic deamidation (7, 8). Importantly, neither
Gln29 nor Gln52, the other two glutamine residues in RhoA, were
modified by CNF1 (7, 8). Deamidation of Gln63 triggers consti-
tutive activation of RhoA, functionally mimicking the GTP-
bound state. Furthermore, the RhoA Gln63Glu variant, which
FIG 1 Schematic representation of enzymatic deamidation in proteins.
Deamidases act on specific residues in the target protein. For all currently
studied bacterial virulence factors, the targets of deamidation are glutamine
side chains, which are converted to glutamic acids. However, it is also possible
for the amide of the side chains of asparagines to be converted to aspartic acid.
Deamidation results in an increase in the negative charge of the target protein,
an increase of approximately 1 Da in the mass of the target protein, and the
release of ammonia. Each of these outputs can be measured experimentally to
characterize the activity of deamidases.
TABLE 1 Bacterial virulence factors that use deamidation to modify host proteins
Protein(s) Species Target(s) Effect
Key
references
Cytotoxic necrotizing factors (CNFs) E. coli, Yersinia pseudotuberculosis Rho GTPases (RhoA, Rac, Cdc42) Activation of Rho GTPases 7, 8
Burkholderia lethal factor 1 (BLF1) Burkholderia pseudomallei eIF4A Inactivation of helicase activity
of translation factor
11
VopC Vibrio parahaemolyticus Rho GTPases (Rac, Cdc42) Activation of Rho GTPases 12
PMT Pasteurella multocida Heterotrimeric G proteins
(Gi, Gq/11, and G12/13)
Activation of G protein
signaling
13




NEDD8 and ubiquitin Inactivation of ubiquitin-
proteasome system
14
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mimics the product of the deamidation reaction, phenocopies
CNF1-treated RhoA upon microinjection into Vero cells (7, 8).
RhoA is not the only target of CNFs. CNF deamidases possess
different GTPase substrate specificities. CNF1 can deamidate Rac
and Cdc42 in vitro and Cdc42 in intact HeLa cells (8, 22). CNF2
can modify RhoA and Rac when coexpressed in E. coli (23). CNF3
can deamidate RhoA, Rac, and Cdc42 in intact HeLa cells treated
with recombinant toxin (24). Although RhoA, Rac, and Cdc42
serve as substrates for CNFY deamidation in vitro, only RhoA
could be deamidated by CNFY in intact cells (25).
Rho GTPases are molecular switches that cycle between an in-
active, GDP-bound state and an active, GTP-bound state (26).
The active state initiates a variety of downstream responses, in-
cluding reorganization of the actin cytoskeleton. Rho GTPases
that are unable to hydrolyze GTP are maintained in a constitu-
tively active state. Activation of different members of the Rho
GTPase family leads to specific effects on the cytoskeleton. RhoA
activation leads to actin reorganization into stress fibers, Rac ac-
tivation causes membrane ruffling, and Cdc42 activation causes
the formation of filopodia (27–29). Treatment with CNF1 induces
stress fiber formation, microspikes, membrane ruffles, and multi-
nucleation in intact cells (7, 8, 22). CNF3 and CNFY also trigger
strong formation of actin stress fibers in intact cells (24, 25). Sur-
prisingly, there is no evidence of CNF3-triggered membrane ruf-
fling or filopodium formation. It has been demonstrated that
CNF1 is required for the invasion of uropathogenic E. coli into
uroepithelial cell monolayers (9). This is consistent with observa-
tions of other bacterial pathogens, such as Salmonella, that attack
the host cytoskeleton to facilitate bacterial entry (10).
The C Terminus of CNF1 Forms a Single Compact Catalytic
Domain
CNFs are modular proteins. The N-terminal domains of these
toxins are required for binding and entry into host cells via recep-
tor-mediated endocytosis (30, 31). The structure of the catalytic C
terminus of CNF1 (residues 720 to 1014) revealed a three-layered
// sandwich, consisting of two mixed 5-stranded -sheets
flanked by two -helices (Fig. 2A) (32). The structure of CNF1
identified a novel overall protein fold that contained an arrange-
ment of residues in the active site reminiscent of the papain-like
superfamily of enzymes, which includes the transglutaminase
blood coagulation factor XIII and GMP synthetase (33). More
recently, it was determined that CNF1 is also structurally similar
to the Thermotoga maritima deamidase protein CheD and a bac-
terial protein of unknown function, YfiH (5). Papain-like super-
family enzymes typically contain a catalytic triad consisting of
histidine, cysteine, and asparagine/aspartic acid. The cysteine and
histidine form a thiolate-imidazolium pair that is critical for acti-
vating the cysteine nucleophile, with the asparagine/aspartic acid
thought to be involved in orienting the histidine. CNF deamidases
contain the invariant cysteine and histidine residues (34). Inter-
estingly, in CNF1, valine is the third member of the catalytic triad,
and this residue is involved in orienting the histidine through a
main chain carbonyl hydrogen bond (32). Structure-based mu-
tagenesis of conserved residues in the catalytic pocket identified
Asn835 and Ser864, which are also required for CNF1 activity
(Fig. 2A) (33). Furthermore, deletion of five individual loop re-
gions surrounding the CNF1 catalytic pocket revealed that loops 8
and 9 are required for deamidation of RhoA (33). Most likely,
Asn835 and Ser864 have indirect roles in catalysis and loops 8 and
9 are important for substrate recognition.
A peptide derived from RhoA residues 59 to 69 could be deami-
dated by CNF1, thus defining the minimal region of RhoA re-
quired for CNF1 deamidation (35). Mutations outside these key
residues did not interfere with the ability of CNF1 to deamidate
RhoA (35). This suggests that CNF1 interacts with a narrow sur-
face of RhoA, and likely other GTPase substrates, and does not
require a significant binding surface for substrate recognition.
BURKHOLDERIA LETHAL FACTOR 1 INHIBITS ACTIVITY OF
TRANSLATION FACTOR eIF4A
Burkholderia lethal factor 1, formerly known as BPSL1549, is a
potent toxin from Burkholderia pseudomallei. Melioidosis is a dis-
ease caused by infection with Burkholderia pseudomallei, a patho-
gen endemic in areas in Southeast Asia and northern Australia
(36). It is associated with severe septicemia and can remain dor-
mant in the host for decades. The molecular basis for the patho-
genicity of B. pseudomallei is poorly understood.
BLF1 interacts with the human translation factor eIF4A in hu-
man cell lysates (11), suggesting that BLF1 might inhibit transla-
tion. This interaction was confirmed by coimmunoprecipitation.
BLF1 reduces endogenous host cell protein synthesis and triggers
increased stress granule formation, which is associated with trans-
lational blocks. In order to determine the outcome of the BLF1-
eIF4A interaction, FLAG-tagged eIF4A was purified from human
cells expressing BLF1. Subsequent mass spectrometric analysis of
eIF4A revealed deamidation of Gln339 to Glu. To determine how
deamidation of this residue altered eIF4A activity, the Gln339Glu
variant was generated. Although this variant was capable of bind-
ing both RNA and ATP and maintained wild-type levels of ATPase
activity, helicase activity was reduced by 47% (11).
The crystal structure of BLF1 revealed an / fold comprising
a sandwich of two mixed -sheets surrounded by loops and -he-
FIG 2 Catalytic domains of diverse deamidases. (A) Catalytic domain of
CNF1 from E. coli (Protein Data Bank [PDB] entry 1HQ0), with invariant
catalytic residues Cys866 and His881 shown in purple. The main chain car-
bonyl of Val833 (also in purple) is involved in coordinating the imidazole ring
of His881. Residues in pink are conserved residues important for CNF1 func-
tion, while loops 8 and 9 (likely important for substrate recognition) are shown
in yellow. (B) BLF1 (PDB entry 3TU8) is a 23-kDa toxin and deamidase that
forms a compact catalytic domain structurally related to those of CNF1 from E.
coli and other papain-like superfamily enzymes. The residues that compose the
catalytic triad (Cys94, His106, and Thr88) are shown in purple. -Helices are
shown in blue, -sheets in green, and loops in gray. All structure figures were
prepared with PyMol.
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lices (Fig. 2B) (11). The -sheet core of the catalytic pocket is
structurally similar to that of the deamidase domain of CNF1,
with a root mean square deviation (RMSD) of 3.9 Å over 170
residues (11). Interestingly, these deamidase domains share only
9% amino acid identity. BLF1 lacks the receptor binding and
translocation domains of CNF1, an expected evolutionary inno-
vation, since the intracellular lifestyle of B. pseudomallei renders
these domains unnecessary. However, the invariant catalytic res-
idues found in CNF1, i.e., cysteine and histidine, are conserved in
the catalytic pocket. The third residue of the catalytic triad in BLF1
is a threonine. BLF1 deamidation of eIF4A and efficient inhibition
of protein translation are dependent on the catalytic cysteine, as
mutation of this residue to a serine renders BLF1 essentially non-
functional (11).
VIBRIO PARAHAEMOLYTICUS TYPE III EFFECTOR VopC
DEAMIDATES SMALL GTPases
A recent addition to the CNF family of deamidases is VopC from
Vibrio parahaemolyticus. V. parahaemolyticus is an enteric patho-
gen that contains two type III secretion systems, namely, TTSS1
and TTSS2 (37); TTSS2 is encoded within a pathogenicity island.
V. parahaemolyticus TTSS2 is necessary and sufficient for invasion
of and replication in both HeLa cells and Caco-2 cells. Among the
type III effectors encoded in the TTSS2 pathogenicity island is
VopC, which shares 20% amino acid identity with the catalytic
domain of CNF from E. coli. As VopC is a type III effector protein,
it does not share the same mechanism for host cell delivery as
CNF1. As a result, VopC and CNF1 have different N-terminal
domains.
Both the catalytic cysteine and histidine residues of CNF1 are
conserved in VopC (Cys220 and His235). Although a VopC struc-
ture has yet to be determined, homology modeling suggests that
the carbonyl oxygen of Leu187 completes the papain-like catalytic
triad. VopC deamidates and constitutively activates the small
GTPases Rac and Cdc42 to facilitate host cell invasion (12). VopC
is not able to activate RhoA. However, as noted above, differences
in substrate specificity are common among CNF homologs. VopC
activates Rac by deamidating Gln61 on the critical switch II do-
main. V. parahaemolyticus invasion of nonphagocytic HeLa cells is
dependent on catalytically active VopC (12).
PASTEURELLA MULTOCIDA TOXIN
PMT Is a Multidomain Toxin, with Catalytic Activity Located
at the C Terminus
Pasteurella multocida toxin (PMT) is a monomeric, 146-kDa en-
zyme. P. multocida causes severe diseases in animals and humans.
It is associated with atrophic rhinitis in pigs and with dermatone-
crosis and respiratory diseases, also known as snuffles, in cattle
and rabbits (38, 39). In humans, P. multocida can cause dermone-
crosis from bite wounds and bacteremia (40).
PMT is a multidomain toxin. The N-terminal region of PMT
has sequence homology with the N termini of CNFs, suggesting
that this region is also used for binding to the host cell surface. In
fact, the first 506 N-terminal residues of PMT are sufficient to bind
to cells and compete with full-length toxin in binding assays (41).
The C-terminal region of PMT contains the catalytic center of
the enzyme and is sufficient for PMT-mediated toxicity when de-
livered into cells by electroporation (41). The crystal structure of
the C-terminal region of PMT reveals a multidomain Trojan
horse-like structure, with the feet, head, and body consisting of
different domains (C1, C2, and C3) that possess different func-
tions (Fig. 3A). The C1 domain, or the feet, consists of seven -he-
lices. The N-terminal -helices of the C1 domain are structurally
similar to the N-terminal domain of Clostridium difficile toxin B
(42). In toxin B, these helices target the protein to the plasma
FIG 3 Crystal structure of the C-terminal region of Pasteurella multocida
toxin. (A) The crystal structure of the C-terminal region of PMT has been
solved (residues 575 to 1285; PDB entry 2EBF). The catalytic region consists of
several domains. The helical C1 domain (purple) forms the “feet” of the Trojan
horse-like structure and contains membrane-targeting properties. The C2
“body” domain contains 2 / subdomains (shown in green and yellow) of
unknown function. The domain responsible for the deamidase activity of PMT
is the C3 “head” C-terminal domain (blue). (B) The crystal structure of the
PMT catalytic domain reveals a disulfide bond between the catalytic cysteine,
Cys1165, and Cys1159 in the binding pocket. Reduction of this disulfide bond
is required for interaction of the catalytic triad and catalytic activity. His1205
and Asp1220 form the other residues of the triad. (C) The crystal structure of
the catalytic domain of PMT(Cys1159Ser) (PDB entry 2EC5) demonstrates
the position of the catalytic triad when the disulfide bond between Cys1159
and Cys1165 is reduced.
Washington et al.
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membrane. Similarly, the first four -helices of C1 are required to
target the catalytic domain of PMT to the plasma membrane (42,
43). Deletion of the C1 domain causes a reduction but not com-
plete loss of PMT function, suggesting that localization to the
plasma membrane is necessary for full PMT-induced toxicity
(42).
The function of the C2 domain, the body of the Trojan horse, is
currently unknown. It is the largest section of the PMT C-terminal
region and consists of two subdomains. Each subdomain contains
typical / folds. Searches using the DALI server revealed possible
structural homology between the second subdomain and phos-
phate-binding enzymes (43). Therefore, the C2 domain may be
enzymatic or may be involved in binding target proteins in the
host cell.
The C3 domain is the catalytic deamidase domain of PMT. Res-
idues Cys1165 plus His1205 (which form the thiolate-imidazo-
lium pair) and His1223 are required for PMT function (44, 45).
Comparison with the structures of other members of the papain-
like superfamily reveals that Asp1220 of PMT is the third residue
of the catalytic triad. Mutation of any of these residues resulted in
a complete loss of PMT function (43). Interestingly, the function
of the catalytic cysteine requires the reduction of a disulfide bond
with Cys1159 (Fig. 3B) (43). Reduction of the disulfide bond be-
tween Cys1159 and Cys1165 causes a rotation of the Cys1165 side
chain toward the catalytic triad (Fig. 3C). Therefore, the disulfide
bond has to be reduced for complete deamidase activity. Addi-
tionally, a Gln1225 residue in the catalytic cleft was shown to be
required for deamidase activity. It has been postulated that this
glutamine forms an oxyanion hole to stabilize the tetrahedral in-
termediate, similar to the role of Gln19 in papain (43).
PMT Deamidation of Heterotrimeric G Protein Families
Affects Several Downstream Signaling Events
Unlike bacterial toxins that have high specificity for their host
targets, such as the CNFs, PMT mediates its virulence effect
through activation of multiple heterotrimeric G protein families.
This leads to a plethora of changes in host signaling that lead to
dysregulation of normal host cell homeostasis. A variety of cell
systems and assays have been used to establish that the pleiotropic
effects of PMT in target cells are due to the ability of PMT to
activate multiple  subunits of diverse heterotrimeric G proteins
(46–56). Heterotrimeric G proteins consist of four major families:
Gs, Gi, Gq/11, and G12/13. When PMT and Gi proteins are
coexpressed in E. coli, PMT modifies Gi via deamidation (13).
PMT converts the conserved Gln205 residue in the switch II re-
gion of Gi to glutamic acid. PMT-mediated activation of Gi
proteins leads to the inhibition of adenylyl cyclase and reduction
of cyclic AMP (cAMP) accumulation (Fig. 4) (49).
PMT activation of Gq/11 proteins results in the stimulation
of phospholipase C (PLC) (Fig. 4). PLC catalyzes the hydro-
lysis of phosphatidylinositol-4,5-bisphosphate to inositol-1,4,5-
triphosphate and diacylglycerol (DAG). It was originally postu-
lated that PMT was capable of activating Gq (56, 57). However,
more recent in vitro expression assays coupled with a mass spec-
trometry output demonstrated that PMT is also able to deamidate
G11 (58). PMT-induced G11 activation of PLC is weaker than
the Gq activation of PLC (59). Therefore, although PMT can
deamidate and activate both Gq and G11 in vitro, the relative
contributions of these activities in vivo may differ. Regardless, ac-
tivation of the Gq/11 subfamily via PMT results in an increased
release of the second messengers inositol-1,4,5-triphosphate and
diacylglycerol, with a consequent increase in calcium mobiliza-
tion. This leads to multiple calcium-mediated responses, such as
activation of protein kinase C and secretion of chloride ions (46,
52, 55). PMT also stimulates the JAK/STAT pathway in a Gq-
dependent manner (48).
PMT also activates the small GTPase RhoA, resulting in reorga-
nization of the actin cytoskeleton and formation of actin stress
fibers (47, 54). PMT induces RhoA indirectly through activation
of multiple heterotrimeric G protein families (Fig. 4). PMT-in-
duced RhoA activation can occur through Gq (55, 56) and
G12/13 (50). A novel cyclic peptide that specifically inhibits Gq
partially blocked PMT-induced RhoA activation (50, 53). Addi-
tionally, PMT-induced RhoA activation was inhibited in G12/13-
deficient HEK293m3 cells (50). However, it was not clear whether
PMT functioned through G12, G13, or both. Recently, mass
spectrometric analysis revealed that PMT can deamidate both
G12 and G13 (58).
Finally, because G activation leads to the release of G from
the heterotrimeric complex, PMT also stimulates increased sig-
naling through G-specific effectors such as phosphoinositide-
3-kinase (Fig. 4) (51).
CYCLE-INHIBITING FACTORS
Members of the Cif Family of Deamidases Are Found in
Many Bacterial Pathogens
Enteropathogenic (EPEC) and enterohemorrhagic (EHEC) E. coli
strains are causal agents of intestinal diarrhea (60, 61). EPEC is the
cause of potentially fatal diarrhea in infants in developing coun-
tries. In contrast, highly infectious EHEC outbreaks occur most
often in developed countries, most notably in North America,
Japan, and Europe. Although the diseases caused by these two E.
FIG 4 PMT deamidates and activates heterotrimeric G proteins. The activa-
tion of diverse G protein-coupled receptor signal transduction pathways by
PMT leads to several phenotypes that are disruptive to the host. PMT activates
Gi, Gq/11, and G12/13 but not Gs. PMT also triggers the release of G
from the heterotrimeric complex, which leads to activation of the phospho-
inositide-3-kinase (PI3K) pathway.
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coli pathovars differ, they both cause the formation of attaching
and effacing (A/E) lesions (60). The genes responsible for attach-
ing and effacing lesions, the type III secretion system and type III
effector genes, are carried on a 35-kb pathogenicity island called
the locus of enterocyte effacement (LEE) (62). However, several
effectors are non-LEE-encoded (Nle) proteins (63). Cif was the
first Nle effector identified in EPEC and EHEC (64).
Cif homologs are encoded in multiple bacterial pathogen ge-
nomes and are all associated with horizontally transferred genetic
elements (64, 65). Cif homologs from Burkholderia pseudomallei,
Yersinia pseudotuberculosis, Photorhabdus luminescens, and Photo-
rhabdus asymbiotica have been named CHBP, CHYP, CHPL, and
CHPA, respectively. Interestingly, these proteins have low pri-
mary amino acid identities to Cif from E. coli: 56% for CHYP, 26%
for CHBP, 23% for CHPL, and 26% for CHPA (65, 66).
Deamidation of NEDD8 by Cif Leads to Disruption of the
Ubiquitin-Proteasome System
CifEc was shown to interact with NEDD8 in a yeast two-hybrid
system, and this interaction was verified by in vitro pulldown and
coexpression assays (14, 67, 68). Cif proteins modify NEDD8 and
ubiquitin via deamidation (14). Ubiquitin and ubiquitin-like
(UBL) proteins, such as NEDD8, control many cellular processes
by targeting various proteins for degradation through the ubiqui-
tin-proteasome system. Ligation of ubiquitin and UBLs such as
NEDD8 to substrate proteins requires a series of three enzymes: an
E1-activating enzyme, an E2-conjugating enzyme, and an E3 li-
gase. Cullin-RING ligases (CRLs) are a large superfamily of E3
ubiquitin ligases (69). The core CRL complex consists of cullin
proteins, which are the scaffold proteins of CRLs and are modified
by NEDD8, and a small RING protein.
In eukaryotic cells, cullins are continuously neddylated and
deneddylated. The conjugation and removal of NEDD8 comprise
an important cycling mechanism that regulates CRL activity. The
COP9 signalosome (CSN), a conserved multiprotein complex
with protease activity, is responsible for cullin deneddylation (69).
When cullins are neddylated, they are maintained in an active,
open conformation that allows substrate proteins to interact with
the Rbx protein at the cullin C terminus (70). This flexible protein
conformation and interaction lead to the ubiquitination and sub-
sequent degradation of target proteins, some of which include
important cell cycle regulators (Fig. 5A).
Cifs target residue Gln40 in NEDD8 and ubiquitin with exqui-
site selectivity (neither Gln39 nor Gln41 of NEDD8 is a target for
deamidation) (14, 71). To date, recombinant CifEc, CifBp, and
CifYp have all been shown to deamidate Gln40 of NEDD8 in vitro
(14, 71). Ectopic expression of the Gln40Glu NEDD8 variant in
HeLa cells phenocopies either the ectopic expression of Cifs or the
effects of Cif during bacterial infection, demonstrating that this
activity is responsible for the Cif-mediated cytopathic phenotype.
The deamidation of NEDD8 by Cif results in a reduction in the
rate of cullin deneddylation (67, 68, 72). The Gln40Glu mutation
in NEDD8 is sufficient to decrease the deneddylation rate by CSN
in the absence of Cif (72). Gln40 is located close to the cullin-
NEDD8 conjugation site. Deamidation of Gln40 in NEDD8 may
prevent CSN-mediated deneddylation of CRLs through interfer-
ence with the global NEDD8-induced conformational change of
cullins (which may be necessary for CSN recognition) (Fig. 5B)
(72). In contrast to previous studies, it was shown in yeast that
CSN can remove deamidated NEDD8 from CRLs more efficiently
than wild-type NEDD8 (73). This causes an increase in deneddy-
lated CRLs. Additionally, it is appropriate to mention that deami-
dation of NEDD8 and subsequent effects on CRL activity have not
been reconstituted in vitro. Therefore, the exact effect of Cif-me-
diated deamidation of NEDD8 remains unclear.
Cif causes cytopathic phenotypes such as rearrangement of the
host cytoskeleton and the formation of actin stress fibers. How-
ever, the hallmark of Cif infection is the inhibition of cell cycle
progression. These multiple cytopathic phenotypes can be attrib-
uted directly to disruption of the ubiquitin-protease system. De-
pending on the stage of the cells during infection, Cifs can arrest
the cell cycle at either the G1/S transition or the G2/M transition
(64, 74). G1/S and G2/M transitions require complexes that consist
of a cyclin and a cyclin-dependent kinase (CDK). Inhibiting CRL
activity prevents ubiquitination and degradation of cell cycle reg-
ulators such as p21 and p27, resulting in inactivation of cyclin-
dependent kinases and cell cycle arrest (64, 74, 75). This triggers
an increase in the inactive and phosphorylated CDKs, leading to
cell cycle arrest (64).
Cifs also inhibit the degradation of a variety of other CRL sub-
FIG 5 Model of Cif inactivation of CRL activity and ubiquitination. (A) In
uninfected cells, the COP9 signalosome (CSN) deneddylates CRLs. NEDD8
(yellow) conjugation and removal represent an important mechanism by
which CRL activity is regulated. When CRLs are neddylated with wild-type
(WT) NEDD8 (green), they are maintained in an open conformation. This
allows substrates (blue) to bind the CRLs, become polyubiquitinated, and then
be degraded. (B) In cells infected with bacteria that express Cif, deamidation of
NEDD8 (yellow) may prevent CRL (green) from forming an open conforma-
tion. This prevents CRLs from associating with the substrate-binding module
that allows downstream ubiquitination and degradation of substrate proteins
(blue) to occur. This may lead to a reduction in the rate of deneddylation and
a decrease in unmodified CRLs (red).
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strates, such as pIB, Cdt1, -catenin, and RhoA (64). Therefore,
inhibition of CRL activity can account for the multiple pheno-
types observed during infection with bacterial species expressing
Cifs.
Multiple Structures Reveal that Cif Proteins Are Members
of the Papain-Like Superfamily
The crystal structures of CifEc, CHBP, CHYP, and CHPL have
been solved (Fig. 6). Although the primary amino acid similarity
among the homologs is low, the structures are highly conserved
(76, 77). The disordered N termini provide type III secretion sig-
nals and are either not included in expressed proteins or not ob-
served in the crystal structures. To date, the only crystal structure
of CifEc includes a truncation of the first 100 amino acids (77). The
overall fold of Cifs comprises a head-and-tail domain organiza-
tion (Fig. 6A). The tail region, also known as the helical extension
domain, is encoded in the N terminus of the protein. The head
domain, also known as the globular core, is formed by the C ter-
minus of the protein. The head domain consists of an antiparallel
-sheet surrounded by -helices. This globular domain displays
overall structural homology to the papain-like superfamily. Sim-
ilar to the other deamidases covered in this review, the active sites
of all Cifs contain an invariant Cys-His thiolate-imidazolium pair.
The third residue of the catalytic triad in Cifs is a glutamine (Fig.
6B). Each of these catalytic residues is required for Cif-induced
cytopathic effects, deamidation of NEDD8 and ubiquitin, and the
resulting increase in stability of the cell cycle regulators p21 and
p27 (14, 65, 66, 77).
An interesting feature observed in the structures of Cifs is the
so-called occluding loop. This loop was first identified in CifEc and
is conserved across the Cif family (76, 77). The occluding loop
partially blocks access to the catalytic site (substrate binding cleft
of papain) and was hypothesized to be important in defining spec-
ificity for Cif substrates (Fig. 6B) (see below).
Cif Deamidases Were the First To Be Cocrystallized with
Their Substrates
The crystal structures of CHYP, CHPL, and CHBP have been de-
termined in complex with NEDD8 (71, 78). Additionally, the co-
crystal structure of CHBP and ubiquitin has also been determined
(71). The structures of these complexes reveal an extensive bind-
ing interface between Cif proteins and their ubiquitin/NEDD8
substrate (Fig. 7A), which involves both the head and tail domains
of Cifs. Multiple alanine mutations in CHBP in the regions that
interface with either the N-terminal -hairpin or the residues ad-
jacent to Gln40 in ubiquitin or NEDD8 were sufficient to abolish
deamidation and Cif-induced cell cycle arrest (71). Furthermore,
alanine mutations in the corresponding residues in ubiquitin and
NEDD8 disrupted both the interaction and deamidation (71). In-
terestingly, all individual alanine mutations in CHYP (that were
tested) were not sufficient to disrupt NEDD8 complex formation.
Only mutations that introduced steric clashes (based on the com-
plex structure) prevented binding (71).
There is very little change in the structures of Cifs bound to their
substrates compared to the uncomplexed states (71, 76, 78). How-
ever, a significant reorientation of the flexible C-terminal tail of
NEDD8 and ubiquitin is observed upon binding by Cifs. Interest-
ingly, it is the occluding loop in Cifs that appears to be responsible
for forcing this reorientation during substrate binding. Displace-
ment of the flexible C-terminal tail is likely important for sub-
strate recognition and for orienting Gln40 in the Cif catalytic
pocket (71, 78). Consistent with this, deletion of the C-terminal
domain of either ubiquitin or NEDD8 diminished deamidation
by Cifs (76). Therefore, multiple areas within the extensive inter-
FIG 6 Crystal structures of cell cycle-inhibiting factors. (A) Crystal structures of Cif deamidases from E. coli (PDB entry 3EFY), B. pseudomallei (PDB entry
3GQM), P. luminescens (PDB entry 3GQJ), and Y. pseudotuberculosis (PDB entry 4F8C). Shown in blue are the -helices of the core globular domain. In teal are
the -helices of the tail helical extension domain. The antiparallel -sheet is shown in green, and the loops are colored gray, except for the occluding loop, which
is colored black. The conserved catalytic residues histidine, cysteine, and glutamine are shown in purple. (B) Amino acids in the catalytic domain of CHBP are
shown as purple sticks.
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face between Cif deamidases and their substrates are important for
activity.
CHBP has a preference for NEDD8 as a substrate (14), and CHYP
deamidation of NEDD8 is 10-fold more efficient than deamidation of
ubiquitin (78). Molecular dynamic studies revealed that this effi-
ciency difference may be due to decreased flexibility of NEDD8 in
complex with Cif compared to ubiquitin (71). Residue Glu31 of
NEDD8 interacts electrostatically with several residues in CHBP. The
residue at the same position in ubiquitin is glutamine, which is not
capable of electrostatic interactions. To determine whether this res-
idue contributes to the difference in movement and deamidation
efficiency, NEDD8(Glu31Gln) and ubiquitin(Gln31Glu) variants
were generated. NEDD8(Glu31Gln) exhibited increased molecu-
lar dynamic motion in simulations, and deamidation efficiency in
in vitro assays was comparable to that observed for wild-type ubiq-
uitin. Conversely, ubiquitin(Gln31Glu) exhibited decreased mo-
lecular dynamic motion, bound more tightly to CHBP, and was
deamidated at a level similar to that of wild-type NEDD8 (71).
Thus, the Gln31 substrate residue may determine the difference in
substrate deamidation efficiency by Cifs.
The data from the Cif-NEDD8 complex structures also suggest
a molecular mechanism of enzymatic deamidation by Cifs (Fig. 7B
and C). All solved structures of currently known enzymatic
deamidases contain conserved papain-like catalytic residues and
/ folds similar to those in the papain-like superfamily. As a
result, the molecular mechanism of deamidation is likely to be
similar to the protease and transglutaminase reactions catalyzed
by other superfamily members. During these reactions, the cata-
lytic histidine residue deprotonates the cysteine sulfhydryl group
to increase its ability to act as a nucleophile. This nucleophile then
attacks the amide substrate, resulting in an acyl-enzyme interme-
diate that is resolved by hydrolysis. The catalytic histidine’s imi-
dazole ring is often coordinated by a hydrogen bond with a third
residue, and this is ensures optimal orientation of the thiolate-
imidazolium pair (Fig. 7B and C) (78).
OspI INHIBITS HOST IMMUNE RESPONSES BY
DEAMIDATING AN E2-CONJUGATING ENZYME
Deamidation of Ubc13 by OspI Inhibits Host Inflammatory
Responses
Shigella species are routinely found in patients suffering from se-
vere diarrhea in developing countries (79). The severe symptoms
associated with Shigella infections are due to the invasion and
destruction of the colonic and rectal epithelium and a severe in-
flammatory reaction (79).
S. flexneri infections trigger changes to the host cell membrane
that initiate the DAG–CBM complex–NF-B signaling pathway.
S. flexneri invades the host cell via macropinocytosis. It is then able
to escape from the phagosome and into the cytoplasm through an
unknown mechanism (80). The escape leads to the accumulation
of host membrane components near the site of infection and to
subsequent host signaling events that lead to inflammation. This
likely occurs through the activation of phospholipases that hydro-
lyze plasma membrane phospholipids, such as DAG, which then
activate protein kinases (81). Subsequently, protein kinases acti-
vate the complex of caspase recruitment domain (CARD), B-cell
lymphoma 10 (BCL-10), and mucosa-associated lymphoid tissue
lymphoma translocation gene 1 (MALT1). This complex is also
referred to as the CBM complex. The CBM complex interacts with
and activates tumor necrosis factor receptor-associated factor 6
(TRAF6). TRAF6 is an E3 ubiquitin ligase that interacts with
Ubc13, an E2 ubiquitin-conjugating enzyme, to form lysine 63
(Lys63)-linked polyubiquitin chains (82). The presence of uncon-
jugated Lys63 polyubiquitin chains activates the complex of trans-
forming growth factor beta-activated kinase 1 (TAK1), TAK1-
FIG 7 Crystal structure of the CifYp deamidase-NEDD8 complex. (A) The
CHYP (-helices are shown in blue, -sheets in green, and loops in gray)-
NEDD8 (red) complex consists of an extensive interaction surface (PDB
entry 4FBJ). The catalytic Cys117 position is modeled based on the
CHYP(Cys117Ala)-NEDD8 complex to demonstrate the proposed molec-
ular mechanism of deamidation. (B) Close-up of the catalytic domain of
CHYP showing that the deamidation target, Gln40 of NEDD8, is posi-
tioned near the Cif catalytic residues (shown in purple). (C) The proposed
molecular mechanism of deamidation involves deprotonation of the cys-
teine by the imidazolium group of histidine (step 1) followed by a nucleo-
philic attack by the thiol group of the catalytic cysteine on the -carbon of
glutamine (step 2).
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binding protein 1 (TAB1), and TAK1-binding protein 2 (TAB2).
This leads to IB phosphorylation and degradation. This allows
NF-B to translocate into the nucleus, where it activates the ex-
pression of proinflammatory cytokine genes (82).
S. flexneri encodes a type III effector, OspI, which modulates
this host response by deamidating Ubc13. Incubation of OspI with
TRAF6, E2 ubiquitin-conjugating enzymes (UBC13 and UEV1A),
and ubiquitin revealed that OspI causes a shift in the mobility of
Ubc13 in SDS-PAGE gels. Mass spectrometry analysis revealed
that Ubc13 is deamidated at residue Gln100 in the presence of
OspI (15). The deamidation of Ubc13 Gln100 blocks its ubiquitin-
conjugating activity, thereby inhibiting the TRAF6-DAG-CBM
complex and subsequent NF-B signaling. This is made evident by
the increase in phosphorylation of the NF-B inhibitor IB and
consequent NF-B translocation to the nucleus in HeLa cells in-
fected with an S. flexneri ospI strain (15). Consistent with this
result, NF-B translocation to the nucleus is inhibited in the pres-
ence of OspI (15).
OspI Forms a Papain-Like Catalytic Pocket That Rearranges
upon Binding Ubc13
The crystal structure of OspI reveals an / fold with four
-strands, seven -helices, and one 310 helix (Fig. 8A) (15). OspI
also shares structural homology with the papain-like superfamily,
as noted above for PMT and the Cif family of deamidases. It is
most closely related to the Pseudomonas syringae cysteine protease
effector AvrPphB (83, 84).
Superimposition of the catalytic domain of AvrPphB with the
OspI crystal structure revealed that the catalytic triad in OspI
comprises Cys62, His145, and Asp160 (15). OspI inhibition of the
DAG–CBM–NF-B pathway is dependent on the catalytic resi-
dues, as mutation of any of these residues leads to the loss of OspI
activity (15).
Recently, the crystal structure of the OspI(Cys62Ala)-Ubc13
complex was solved (Fig. 8B and C) (85). This structure revealed
an extensive binding surface between OspI and Ubc13 that covers
11% of the exposed surface of OspI (85). A negatively charged
region and a hydrophobic pocket of OspI bind -helix 1 and the
L1 and L2 loops of Ubc13, respectively. Analysis of point muta-
tions in these regions revealed that both interfaces are required for
deamidation of Ubc13 (85). In contrast to the case for Cifs, signif-
icant structural rearrangements occur in the catalytic pocket of
OspI upon substrate binding (85). In uncomplexed OspI, the cat-
alytic pocket is blocked by Asn61 (Fig. 8A). When OspI binds
Ubc13, Asn61 rotates approximately 180 degrees. This leads to
formation of a hydrogen bond with Asn54 and to repositioning of
Ala62. The movement of these residues opens the pocket, allowing
insertion of Gln100 from Ubc13 into the catalytic site. Superposi-
tion of the catalytic pockets of AvrPphB and Ubc13-bound OspI
reveals an overlap of OspI Ala62 (Cys62 in the wild-type protein)
and the catalytic cysteine of AvrPphB (85). This suggests that the
remodeled OspI catalytic pocket (bound to Ubc13) contains the
proper orientation for catalytic activity. Additionally, Phe95 and
His96 of OspI reorient to form a hydrophobic pocket that inter-
acts with Ubc13 loops L1 and L2 (85).
The OspI-Ubc13-complexed structure confirms that the mo-
lecular mechanism of OspI is similar to that of papain-like en-
zymes and that suggested for Cif/NEDD8 deamidation (Fig. 7C)
(84–86). It is interesting that the catalytic cysteine is capable of
forming disulfide bonds with Cys65 (Fig. 8C) (15). Although it has
not been demonstrated that this disulfide bond affects the func-
tion and positioning of the catalytic cysteine, it is possible that it
maintains the deamidase in a noncatalytic state under nonreduc-
ing conditions, as has been demonstrated for PMT (Fig. 3B and C)
(43).
CONCLUSIONS
Recently, it was discovered that deamidation is a common mode
of action used by several bacterial virulence factors to modify the
functions of host proteins. Deamidation, as an irreversible modi-
fication of host proteins, offers many advantages to invading
pathogens. Unlike the case of phosphorylation, host systems lack
the ability to reverse the effects of deamidation. This makes
deamidases particularly potent virulence factors. Characterized
deamidases have been shown to modify specific residues on host
proteins that are key to the host protein’s function. Additionally,
there is high specificity in the proteins that are targeted by deami-
dases, as can be seen in the ability of CNF1 to deamidate some, but
not all, Rho GTPases. Although the deamidation modification is
subtle and specific, the downstream impacts on host cell function
are extensive. This is most evident in the case of cycle-inhibiting
factors, which inhibit the ubiquitin-proteasome system, leading to
both cell cycle arrest and cytoskeletal rearrangements. In fact, it is
apparent that bacterial deamidase virulence factors have evolved
to target key modulators of critical cell signaling systems in hosts.
However, our understanding of the role of deamidases in bac-
terial virulence is still in its infancy. Further elucidation of the
molecular mechanisms and the interactions between deamidases
and their substrates is important. To date, the use of enzymatic
deamidation as a generic “housekeeping” mechanism for modify-
ing protein function has been documented only for prokaryotes.
Do eukaryotes also use this activity to modulate protein activity?
Or is enzymatic deamidation in eukaryotic cells an innovation of
bacterial pathogens mediated via translocated proteins? Future
work would be aided greatly by new methods for easier identifica-
tion of deamidation. Current methods require knowledge of the
specific substrate of each deamidase in order for activity to be
assayed. This differs from enzymes such as cysteine proteases, for
which cleavage of generic substrates can easily be measured. Ad-
ditionally, the presence of nonspecific deamidation in protein
samples can make the identification of enzymatic deamidation
difficult. Another important future direction is to define the mo-
lecular mechanisms by which deamidation specifically affects the
functions of host cell targets. At present, our knowledge is re-
stricted to observing the phenotypic outcomes of deamidation on
particular targets during diverse steps in the lifestyles of diverse
pathogens. It would be valuable to understand how deamidation
alters function at the level of the modified protein. For example, G
proteins are common targets of at least some of the deamidases
discussed here. But is the phenotypic outcome of these events
always merely an irreversible loss of catalytic function, or could
the deamidated G protein now act as a dominant-negative variant
on its normal cellular partners, amplifying the impact of the
deamidation event to multiple output pathways, as noted above
for PMT? Such understanding will be important, for example, in
exploration of genome editing to target glutamine-to-glutamate
mutations.
Regardless of the challenges of these studies, it is clear that
tackling the molecular mechanisms of deamidation, as has been
done for other posttranslational modifications used by bacterial
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pathogens, is essential for our understanding of bacterial patho-
genesis and, in fact, for the normal host cell biology of their tar-
gets.
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